Quick Answer
LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Operating Income Loss of -$5.11 million for the year ending 2025.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed a decrease of -43.0% in Operating Income Loss from 2024 to 2025.
- This data is from LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s Operating Income Loss has declined by 479.3%.
- Historical annual values: Fiscal year 2025: -$5.11 million | Fiscal year 2024: -$3.57 million | Fiscal year 2023: -$5.09 million | Fiscal year 2022: -$6.31 million | Fiscal year 2021: -$6.72 million | Fiscal year 2020: -$3.27 million | Fiscal year 2019: -$2.49 million | Fiscal year 2018: -$2.14 million | Fiscal year 2017: -$1.81 million | Fiscal year 2016: -$2.13 million | Fiscal year 2015: -$2.65 million | Fiscal year 2014: -$2.40 million | Fiscal year 2013: -$1.37 million | Fiscal year 2012: -$2.11 million | Fiscal year 2011: -$1.87 million | Fiscal year 2010: -$881.7 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: